This retrospective study was approved by the institutional Review Board of the Korea University Anam Hospital, Seoul, Korea (IRB number: 2021AN0525), and conducted in accordance with the tenets of the Declaration of Helsinki. We reviewed the medical records of consecutive patients diagnosed with acute VKH disease between May 2016 and October 2021. During the initial episode, each patient was diagnosed with VKH disease based on the revised diagnostic criteria for VKH disease
22 after a comprehensive ophthalmic examination, including slit-lamp biomicroscopy, fundoscopy, color fundus photography, fluorescein angiography, indocyanine green angiography, swept-source OCT (SS-OCT), and OCT angiography (OCTA). In the acute uveitic stage, all patients were treated with high-dose intravenous (methylprednisolone, 1000 mg/day for three days) or oral (1.0–1.5 mg/kg/d) corticosteroid therapy, followed by a slow tapering (2.5–10 mg/wk) with oral corticosteroids over a period of six to nine months. All but two patients received an additional immunosuppressive agent (cyclosporine or mycophenolate mofetil) from the initial episode or after disease recurrence. During the follow-up period, each patient underwent a comprehensive ophthalmic examination, which included slit-lamp biomicroscopy, fundus examination, color fundus photography, SS-OCT, and OCTA, but not fluorescein angiography and indocyanine green angiography.
For the analysis, we selected OCT images obtained from patients in the convalescent stage of the disease without active inflammatory signs. When several OCT images were available, we selected those obtained at the last visit. All eyes with VKH disease were divided into SGF-positive and SGF-negative groups based on clinical documentation and fundus photographs. Fundus photographs were evaluated by the consensus of two retinal experts (Y.K. and J.O). As normal controls, age- and sex-matched subjects were included from the same database. We randomly selected one of the two eyes from subjects without ocular disease or included the normal fellow eyes of subjects with unilateral ocular disease such as epiretinal membrane, retinal vein occlusion, and retinal tears. All eyes in the normal control group had a best-corrected visual acuity of 20/20 or better (Snellen), and no evidence of chorioretinal and optic nerve disease, as confirmed by medical records, fundus photography, SS-OCT, and SS-OCTA. The exclusion criteria for normal controls included the presence of comorbid chorioretinal pathologies in any of both eyes, including but not limited to age-related macular degeneration, central serous chorioretinopathy, uveitis, diabetic retinopathy, hypertensive retinopathy, and high myopia (spherical equivalent ≥ −6.00 diopters). Eyes that had undergone ocular laser treatment or surgery were also excluded.